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Improved early detection of ovarian cancer using longitudinal
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Jatinderpal Kalsi1,4, Usha Menon4, Ian Jacobs1,5, Alexey Zaikin1,2,6,7 and John F. Timms 1
BACKGROUND: Ovarian cancer has a poor survival rate due to late diagnosis and improved methods are needed for its early
detection. Our primary objective was to identify and incorporate additional biomarkers into longitudinal models to improve on the
performance of CA125 as a ﬁrst-line screening test for ovarian cancer.
METHODS: This case–control study nested within UKCTOCS used 490 serial serum samples from 49 women later diagnosed with
ovarian cancer and 31 control women who were cancer-free. Proteomics-based biomarker discovery was carried out using pooled
samples and selected candidates, including those from the literature, assayed in all serial samples. Multimarker longitudinal models
were derived and tested against CA125 for early detection of ovarian cancer.
RESULTS: The best performing models, incorporating CA125, HE4, CHI3L1, PEBP4 and/or AGR2, provided 85.7% sensitivity at 95.4%
speciﬁcity up to 1 year before diagnosis, signiﬁcantly improving on CA125 alone. For Type II cases (mostly high-grade serous),
models achieved 95.5% sensitivity at 95.4% speciﬁcity. Predictive values were elevated earlier than CA125, showing the potential of
models to improve lead time.
CONCLUSIONS: We have identiﬁed candidate biomarkers and tested longitudinal multimarker models that signiﬁcantly improve
on CA125 for early detection of ovarian cancer. These models now warrant independent validation.
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BACKGROUND
Ovarian cancer is the sixth most common cancer in women,
causing 152,000 deaths worldwide annually. The overall 5-year
survival rate is ~40% due to late presentation, with the majority of
cases diagnosed at stage III and IV, where the 5-year survival rate
is only 3–19%. Stage I and II ovarian cancers have 5-year survival
rates of 40–90%.1 Earlier detection of ovarian cancer, in particular
aggressive tumours, is a possible way to improve outcomes.
Ovarian malignancies can be divided into two types differing by
origin and molecular subtype and are associated with differing
prognosis.2,3 Type I cancers can arise from tumours of low malignant
potential, remain low grade, are slower growing and have a more
favourable outcome. Type II cancers are typically high grade,
aggressive, associated with poor survival, and are characterised by
loss-of-function mutations of TP53 and BRCA1/2 and thus display
genomic instability.4 It is well established that Type II cancers (mainly
high-grade serous cancers) account for most ovarian cancer
mortality and early detection of these tumours is likely to translate
into mortality beneﬁt.
Two tests used clinically to detect ovarian cancer are serum
cancer antigen 125 (CA125) and transvaginal ultrasound. Both have
limitations of speciﬁcity and sensitivity. CA125 is often elevated in
benign conditions such as endometriosis and ovarian cysts and is
not always detectable in early-stage disease. This has limited
CA125’s potential as an accurate biomarker for early detection.5–8
Human epididymis secretory protein E4 (HE4/WFDC2), another Food
and Drug Administration-approved biomarker for differential
diagnosis of ovarian cancer, has similar limitations in detecting
early and asymptomatic cancers.9–11
Multimarker tests have been shown to improve performance for
ovarian cancer diagnosis compared to CA125 or HE4 alone.12,13
For example, the Risk of Ovarian Malignancy Algorithm, combin-
ing CA125 and HE4 for determining malignancy during pre-
operative assessment, had a sensitivity of 88% compared to 63%
and 78%, respectively, for CA125 and HE4 alone.14–16 Of more
relevance, it has been shown that annual screening using serial
serum measurements of CA125 in the Risk of Ovarian Cancer
Algorithm (ROCA) within the UK Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS) provides an increased detection rate
over CA125 cut-off models with a stage-shift in the detected
cancers.17,18 Although the trial did not report a signiﬁcant beneﬁt
in mortality through screening, there was an indication of a 15%
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mortality beneﬁt, which awaits conﬁrmation with further follow-
up.19,20 Given the limitations of current ‘gold standards’ in ovarian
cancer detection, there is an urgent need for new biomarkers. The
incorporation of these into longitudinal algorithms with CA125
may be a promising strategy for improving early detection of
ovarian cancer. We have previously described the Method of Mean
Trends (MMT) algorithm, which provided high performance in
predicting ovarian cancer based on serial CA125 measurements21
and have now adapted this to include multiple serial biomarker
measurements.
Herein, we present the discovery of potential new serum
biomarkers and longitudinal multimarker models capable
of discriminating cancer-free controls and ovarian cancer
cases prior to clinical diagnosis. We used 490 serial serum
samples from 49 ovarian cancer cases taken at different times
prior to diagnosis and 31 matched non-cancer controls nested
within UKCTOCS, applying multidimensional liquid chromato-
graphy tandem mass spectrometry (LC-MS/MS) with tandem
mass tagging for biomarker discovery. Promising candidates
from this and the literature were assayed in all serial
samples from these women and combined with CA125, and
the data was used to generate longitudinal multimarker models.
Using this novel approach, we show both increased sensitivity
for ovarian cancer detection and earlier detection than using
CA125 alone.
METHODS
Sample set
The study set comprised serum from women recruited to
UKCTOCS collected according to a standard operating proce-
dure.17 Trial participants at enrolment were post-menopausal
women aged 50–74 years who had no family history of ovarian
cancer. Women subsequently diagnosed with ovarian cancer
were identiﬁed by cross-referencing with the Health and Social
Care Information Centre cancer registry and death codes, with
diagnosis conﬁrmed by review of histopathology reports. Forty-
nine cases from the multimodal arm of UKCTOCS were selected
comprising 10 borderline (BL) cases, 9 Type I cases and 30 Type II
cases (Table 1). Thirty-one matched controls from the multimodal
arm were selected who had no history of cancer and were
matched to Type II cases based on age (±5 years), collection
date (within 6 months), and collection centre. All serial samples
from these women (n= 490) were retrieved from cryostorage,
shipped on dry ice to the laboratory, and stored at −80 °C prior
to analysis.
LC-MS/MS discovery analysis
Samples were pooled into six groups for MS-based discovery,
comprising ‘late’ (<14 months to diagnosis) and ‘early’
(>35 months to diagnosis) samples for each cancer case and
control: Type I/BL early and late, Type II early and late, control
Table 1. Sample set characteristics.
(A) Characteristics of sample/patient cohort with cancer morphology, grade and Type
Cases Controls
No. of individuals 49 31
No. of samples 315 175
Mean age at sample draw (years) (range) 66.4 (50.6–79.7) 65.0 (51.4–79.2)
Median time to diagnosis (months) (range) 26.27 (2.27–97.51) na
Morphology—grade (Type)
Serous—High grade (Type II) 23
Endometrioid—High grade (Type II) 3
Carcinosarcoma—High grade (Type II) 1
Not speciﬁed—High grade (Type II) 3
Endometrioid—Low grade (Type I) 5
Clear cell—High grade (Type I) 3
Not speciﬁed—Low grade (Type I) 1
Borderline (mixed morphologies) 10
(B) Characteristics of sample groups used for discovery proﬁling
Sample set Sample group No. of cases No. of samples Mean age
(years)
Mean time to
diagnosis (months)
Mean BMI Modal FIGO
stage
Discovery Type I/BL ‘late’ 9/10 9/10 68.1/70.1 8.8/4.7 28.4/26.04 Ia/Ia
Type II ‘late’ 30 30 67.1 5.5 26.8 IIIc
Control ‘late’ 31 31 67.1 na 25.7 na
Type I/BL ‘early’ 9/10 9/10 64.8/65.2 48.3/62.8 28.4/26.04 Ia/Ia
Type II ‘early’ 30 30 62.5 60.4 26.8 IIIc
Control ‘early’ 31 31 62.7 NA 25.5 na
All annual samples Type I 9 36 67.6 30.7 27.9 Ia
Type II 30 144 64.5 37.8 26.4 IIIc
Controls 31 158 64.7 na 25.4 na
Only annual screening samples were used for biomarker algorithm development
BL borderline ovarian cancers
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early, and late (Table 1B). A pooling approach was taken, as the
analysis of individual samples with extensive fractionation is not
feasible in terms of time and cost-effectiveness. Details of the
method can be found in Supplementary Materials and Methods.
Brieﬂy, pools were sequentially immunodepleted of the top 20
most abundant serum proteins, digested with trypsin, labelled
in 6-plex using TMT reagents, and extensively fractionated
(100 fractions) by strong anion exchange and high pH reversed-
phase LC, prior to LC-MS/MS analysis on orbitrap instruments,
essentially as described.22 Raw data ﬁles were combined and
analysed using the Proteome Discoverer V1.4 software with
database searching using the Mascot search engine V2.4. Data
were ﬁltered and reporter ion-based relative quantiﬁcation of
protein groups applied to compare expression across the six
groups. A biomarker scoring system was applied to aid in
candidate selection, ranking the proteins based on magnitude
and consistency of expression differences, data quality, and
biological function (see Supplementary Materials). The full data
set and scoring system is available as Supplementary Data File S1.
Serum assays
Serum concentrations of biomarker candidates were quantiﬁed
using commercial enzyme-linked immunosorbent assays (ELISA)
or chemiluminescence immunoassays. Kits were ﬁrst tested on
pooled samples according to the manufacturers’ instructions
to deﬁne optimal dilutions and assay reproducibility. The kits
used, catalogue numbers, dilutions, and intra-assay coefﬁcient of
variations were: Human AGR2 ELISA Kit (ElabScience; E-EL-H0298;
1:20; 18%), CA125 ECLIA assay (Roche; Elecsys CA 125 II; 1:1; 4%),
CHI3L1 Quantikine ELISA Kit (R&D Systems; DC3L10; 1:50; 14%),
DNAH17 (human) ELISA Kit (EIAab; E5886h, 1:5; 17%), FSTL1 ELISA
Kit (USCN; SEJ085Hu; 1:100; 11%), Glycodelin/PP14 Elisa Kit
(Bioserv Diagnostics; BS-30-20; 1:2; 22%), HE4 ECLIA assay (Roche;
Elecsys HE 4; 1:1; 8%), LRG1 ELISA Kit (IBL; 27769; 1:2000; 16%),
Human PEBP4 ELISA Kit (ElabScience; E-EL-H5440; 1:200; 20%), and
SLPI Quantikine ELISA Kit (R&D Systems; DP100, 1:50; 12%).
Model building, testing and statistical analysis
R software was used for model building and statistical analysis.
T test or Mann–Whitney test was performed for parametric or
non-parametric values, respectively, as determined by the
D’Agostino and Pearson omnibus normality test. All marker
values were log10-transformed for model generation. To generate
longitudinal, multimarker models, for each individual, serial
biomarker values from annual samples (taken <5 years to
diagnosis) were ﬁrst transformed into a single value that
represented the degree of change over time of the candidate
marker using one of the four indices (Fig. 1). Index 1{1} determines
the average weighted gradient between consecutive pairs of
values (mean derivative). Index 2{2} is the average product of the
difference in age and marker concentration, representing the area
under the time series. Index 3{3} is the coefﬁcient of variance and
does not use time as a factor. Index 4{4} is the sum of the product
of patient age and marker concentration divided by the sum of
ages at which the sample was taken (i.e., the centre of mass) and
thus would reduce any effect of age on marker concentration,
should such a relationship exist. We have previously described
these indices and used them to build the MMT algorithm, based
on serial CA125 measurements.21 Here indices were applied to all
candidate measurements and, together with raw measurements
(Index 5{5}), subjected to variable selection using a robust
methodology that included Akaike Information Criterion (AIC),
least absolute shrinkage and selection operator (lasso), boot-
strapped lasso, mean accuracy decrease, and Gini impurity. AIC
selection was performed using the standard implementation from
package MASS in R. For lasso, the penalty parameter lambda was
chosen as the ﬁrst value which left only 3 variables in the model
starting from 0 with 0.01 steps. In bootstrap lasso, 200 re-
samplings were created from the original data and the traditional
lasso approach applied to each of them. For each variable, the
frequency of inclusion in the top three re-samplings was reported.
Standard implementation of the mean accuracy decreases and
Gini impurity was used from the randomForest package in R. This
process identiﬁed the variables that could potentially serve as
‘good’ predictors in our models. All combinations of these
predictors were then tested as logistic regression models, limiting
the number of variables to three to avoid overﬁtting. The Caret
package in R was used for leave-one-out cross-validation for
selection of the best models. Models were then ﬁtted on
the whole data set and comparisons of sensitivity for the
longitudinal models at ﬁxed high speciﬁcity (>90% and >95%)
were performed using McNemar’s test. Conﬁdence intervals for
sensitivity were generated by 2000 stratiﬁed bootstrap replicates23
for visual comparison. Model calibration was assessed
with the Hosmer–Lemeshow goodness-of-ﬁt test, with
P values < 0.05 indicating a poorly calibrated model.
Average weighted gradient between consecutive 
pairs of values (mean derivative)
Average product of the difference in age and marker 
concentration (area under the time series)
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Index 1 {1}
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Fig. 1 Longitudinal trend indices used for transforming serial data. For every ith patient, ki is the total number of serial measurements, yi,j is
the jth serial measurement and ti,j and ti,ki represent, respectively, ages at which the current and the most recent measurements were taken.
A simple cut-off for the ﬁnal measurement of each candidate marker was used as Index 5{5}.
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RESULTS
MS-based proﬁling of pre-diagnosis serum samples
A set of 490 serum samples was sourced from the UKCTOCS
biobank comprising serial samples from 49 volunteers who were
later diagnosed with BL (n= 10), Type I (n= 9) or Type II (n= 30)
ovarian malignancy (Table 1). Serial samples were also taken from
matched cancer-free controls (n= 31). All women were aged >50
years and post-menopausal with no signiﬁcant difference in age
between the case and control groups. The majority of Type II
cancers were high-grade serous (n= 23) with Type I cancers
comprising low-grade endometrioid (n= 5), clear cell (n= 3) and
low-grade unspeciﬁed (n= 1). Paired samples from these volun-
teers (n= 160) taken <14 months (‘late’) and >35 months (‘early’)
prior to diagnosis and from matched controls (Table 1B) were
pooled by cancer Type and time group and subjected to
immunodepletion, tryptic digestion, 6-plex TMT-labelling and
extensive peptide fractionation prior to LC-MS/MS-based proteo-
mic proﬁling. TMT labelling efﬁciency was >99% with labelling in
each TMT channel between 91.3% and 92.8%. This analysis yielded
748 protein groups quantiﬁed across all six sample groups. There
were notable differences in protein expression and scores
between the Type I/BL and Type II groups, possibly reﬂecting
differences in tumour molecular proﬁles and the heterogeneity of
the Type I/BL cases. Particularly, several acute-phase response
proteins (e.g., A1AT, CRP, HP, ORM1, ORM2 and SAA1) were more
highly upregulated in the Type I/BL group towards diagnosis,
suggesting that Type I and/or BL disease is characterised by a
more inﬂammatory phenotype.
Candidate selection and univariate testing
Five high-scoring candidates were selected for further testing based
on functional assignment and availability of suitable commercial
assays: chitinase-3-like protein 1 (CHI3L1/YKL40), dynein heavy chain
17 (DNAH17), follistatin-related protein 1 (FSTL1), leucine-rich alpha-
2-glycoprotein (LRG1), and phosphatidylethanolamine-binding pro-
tein 4 (PEBP4). Our previous identiﬁcation of CHI3L1 as a possible
marker of early ovarian epithelial cell transformation24 also
supported the choice of candidate. Four further proteins
were selected based on previous studies: anterior gradient protein 2
(AGR2) homologue,25 human epididymis 4 (HE4/WFDC2),14,26
glycodelin (PAEP),27–29 and antileukoproteinase (SLPI).30,31 Assays
were performed on all 490 serial samples from the 80 cases and
controls to generate serial data (Supplementary Material; Fig. S1).
Measurements for serum CA125 taken from UKCTOCS were also
included in the analysis. We found no correlation between the
concentration of any candidate and time from sample collection to
spin (Pearson’s correlation coefﬁcient, R < |0.2|), discounting any
possible confounding effects of sample processing. In comparing
late and early time groups used for LC-MS/MS discovery, CA125, HE4
and glycodelin distinguished cases from controls in the late time
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Fig. 2 Tukey box and whisker plots showing changes in pre-diagnostic serum candidate biomarker levels in cases and controls in two-
time groups; <14 months to diagnosis (late) and >35 months to diagnosis (early). a AGR2 serum levels; b LRG1 serum levels; c CHI3L1
serum levels; d FSTL1 serum levels; e SLPI serum levels; f DNAH17 serum levels; g PEBP4 serum levels; h CA125 serum levels; i HE4 serum
levels; j glycodelin serum levels. *P < 0.05, **P < 0.001 from either t test or Mann–Whitney test. Data for borderline cases are omitted.
Axis labels: C= controls; I= Type I; II= Type II; L= late; E= early.
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group and between the late and early time groups for Type II cases
(Fig. 2h–j). PEBP4 distinguished Type II cases from controls in the
late group (P= 0.02) and Type I cases from controls in the early
group (P= 0.034) (Fig. 2g). No other candidate gave signiﬁcant
differences (P < 0.05), although trends were evident for some.
Generation and testing of multimarker longitudinal models
Longitudinal analysis may increase the predictive capability of
biomarkers.18 To address this, we ﬁrst binned samples into pre-
diagnosis time groups of ≤15, 15–30, 30–45 and >45 months and
tested logistic regression models using log-transformed values,
including up to 3 marker candidates or epidemiological variables
(age, body mass index, oral contraceptive pill use, and hormone
replacement therapy use) in the models. After leave-one-out
cross-validation, these models failed to show any clinically
signiﬁcant improvement on CA125 alone (Supplementary Material;
Table S1). We therefore undertook a novel longitudinal
approach,21 whereby four trend indices ({1}–{4}) describing
changes in concentration over time were used to transform the
measurements for each candidate into a single value (Fig. 1). Only
data from annual screening samples was used to eliminate
potential bias from repeat CA125 testing triggered by ROCA in
UKCTOCS and data for BL cases were also excluded. Summary
statistics for the indexed biomarker values are presented in
Tables S2 and S3.
Multimarker models may improve classiﬁcation over single-
marker tests. Therefore, following rigorous variable selection
(Table S4), logistic regression was used to combine longitudinal
index-transformed marker values, using a maximum of three main
effects to avoid overﬁtting and applying leave-one-out cross-
validation. Models were then evaluated using all cases whose ﬁnal
annual screening sample fell within 1 year to diagnosis. Samples
taken >5 years before diagnosis were also excluded, leaving serial
samples from 6 Type I and 22 Type II cases for comparison with
serial samples from the 31 controls. Median sensitivities at ﬁxed
speciﬁcity (90.3% and 95.4%) were determined for each model
with 95% conﬁdence intervals (CIs) calculated by bootstrapping.
Goodness-of-ﬁt testing showed that the CA125{5} model was
poorly calibrated (P= 0.04), while all multimarker models were
well calibrated (P values ranging from 0.343 to 0.975). Model
sensitivities were then compared to CA125 cut-off model CA125
{5}, using McNemar’s exact test.
Considering all cases, three models combining CA125 with
PEBP4, AGR2, CHI3L1 and/or HE4 gave signiﬁcantly higher
sensitivities (P < 0.05) at 90.3% speciﬁcity up to 1 year before
diagnosis than CA125 alone (Table 2A, Fig. 3a, Table S5). At 95.4%
speciﬁcity, while no model was signiﬁcantly better than CA125
(best P value= 0.055), all had sensitivities >82%; the 2 best
models (CA125{3}AGR2{3}CHI3L1{3} and CA125{3}CHI3L1{3}HE4{5})
had 87.5% sensitivity at 95.4% speciﬁcity, missing only 2 cases
Table 2. Performance of top models based on leave-one-out-cross-validation.
Model AUC (95% CI) Sensitivity (95% CI) at 0.903 speciﬁcity Sensitivity (95% CI) at 0.954 speciﬁcity
(A) All cases up to 1 year to diagnosis
CA125{5} 0.869 (0.775–0.962) 0.714 (0.536–0.857) 0.643 (0.429–0.857)
CA125{3}CA125{4}PEBP4{5} 0.96 (0.923–0.997) 0.929 (0.75–1) 0.821 (0.643–0.964)
CA125{3}CHI3L1{3}HE4{1} 0.959 (0.916–1) 0.929 (0.786–1) 0.821 (0.643–0.964)
CA125{3}CHI3L1{3}HE4{5} 0.96 (0.922–0.998) 0.929 (0.786–1) 0.857 (0.571–0.964)
CA125{3}AGR2{3}CHI3L1{3} 0.966 (0.938–0.995) 0.929 (0.786–1) 0.857 (0.5–0.964)
CA125{3}HE4{4}HE4{5} 0.974 (0.95–0.997) 0.929 (0.786–1) 0.821 (0.679–0.964)
(B) Type II cases up to 1 year to diagnosis
CA125{5} 0.868 (0.756–0.979) 0.727 (0.546–0.909) 0.682 (0.455–0.864)
CA125{3}CA125{4}PEBP4{5} 0.97 (0.934–1) 0.955 (0.773–1) 0.818 (0.636–1)
CA125{3}CHI3L1{3}HE4{1} 0.986 (0.973–0.999) 1.0 (0.909–1) 0.909 (0.727-1)
CA125{3}CHI3L1{3}HE4{5} 0.984 (0.97–0.998) 1.0 (0.909–1) 0.955 (0.636–1)
CA125{3}AGR2{3}CHI3L1{3} 0.984 (0.971–0.998) 1.0 (0.909–1) 0.955 (0.636–1)
CA125{3}HE4{4}HE4{5} 0.988 (0.976–1) 1.0 (0.864–1) 0.909 (0.727–1)
(C) All cases at 1–2 years to diagnosis
CA125{5} 0.507 (0.382–0.631) 0.094 (0–0.281) 0 (0–0.094)
CA125{3}CA125{4}PEBP4{5} 0.658 (0.543–0.772) 0.313 (0.125–0.5) 0.188 (0.063–0.375)
CA125{3}CHI3L1{3}HE4{1} 0.648 (0.531–0.765) 0.281 (0.125–0.438) 0.156 (0.031–0.313)
CA125{3}CHI3L1{3}HE4{5} 0.65 (0.54–0.789) 0.25 (0.094–0.469) 0.188 (0.031–0.344)
CA125{3}AGR2{3}CHI3L1{3} 0.697 (0.595–0.8) 0.375 (0.156–0.532) 0.188 (0–0.406)
CA125{3}HE4{4}HE4{5} 0.649 (0.532–0.766) 0.313 (0.156–0.531) 0.25 (0.063–0.438)
(D) Type II cases at 1–2 years to diagnosis
CA125{5} 0.504 (0.361–0.648) 0.08 (0–0.24) 0 (0–0.12)
CA125{3}CA125{4}PEBP4{5} 0.632 (0.499–0.765) 0.24 (0.08–0.48) 0.16 (0.04–0.32)
CA125{3}CHI3L1{3}HE4{1} 0.65 (0.523–0.778) 0.2 (0.04–0.44) 0.08 (0–0.28)
CA125{3}CHI3L1{3}HE4{5} 0.643 (0.519–0.766) 0.24 (0.04–0.48) 0.16 (0–0.32)
CA125{3}AGR2{3}CHI3L1{3} 0.71 (0.6–0.82) 0.36 (0.12–0.56) 0.16 (0–0.4)
CA125{3}HE4{4}HE4{5} 0.644 (0.517–0.772) 0.24 (0.08–0.44) 0.16 (0.04–0.36)
Area under the ROC curve (AUC) is given with 95% conﬁdence intervals (CI) calculated using the method of DeLong. Sensitivities are given at speciﬁcities of
0.903 and 0.954 with 95% CI calculated by bootstrapping with 2000 stratiﬁed replicates
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(Fig. 3d, e). Considering Type II cases only, 4 models gave 100%
sensitivity at 90.3% speciﬁcity (Table 2 and Fig. 3a) and all models
performed signiﬁcantly better than CA125 alone (Table S5). The
two best models (above) provided 95.5% sensitivity at 95.4%
speciﬁcity (Table 2B and Fig. 3a), signiﬁcantly outperforming
CA125 (Table S5). Thus we demonstrate longitudinal multimarker
models with signiﬁcantly improved performance over CA125
alone for detecting ovarian cancer up to 1 year before diagnosis.
The capacity of models to predict ovarian cancer earlier than 1
year before diagnosis was next investigated. Performances were
evaluated within 1–2 years of diagnosis after excluding samples
taken within 1 year of diagnosis. All longitudinal models had
sensitivities >25% at 90.3% speciﬁcity, although none were
signiﬁcantly better than CA125 alone (Table 2C, Fig. 3b, Table S5).
The best model (CA125{3}AGR2{3}CHI3L1{3}) provided 37.5%
sensitivity (all cases) and 36% sensitivity (Type II cases) at 90.3%
speciﬁcity versus 9.4% and 8.0%, respectively, for CA125 alone.
Plotting prediction values against time to diagnosis showed that
the models detected cancer earlier than CA125 (Fig. 4). Models
CA125{3}AGR2{3}CHI3L1{3} and CA125{3}HE4{4}HE4{5} were the
best for Type II cases, providing test positivity 18 and 15 months
earlier, respectively, than CA125. The data show the potential of
the models to improve on the lead time of detection.
DISCUSSION
While elevated serum CA125 is a reasonably robust marker for
detecting ovarian cancer, it is not always raised in early-stage
disease and can be elevated in benign conditions. This
necessitates the discovery of complementary biomarkers and
algorithms that together with CA125 will improve early detection
of ovarian cancer. Herein we have identiﬁed new candidate
biomarkers using a set of pre-diagnosis serum samples nested
within UKCTOCS and generated longitudinal data for these
markers. The data were then used to develop novel longitudinal
models capable of identifying ovarian cancer cases that were
undetectable using CA125 alone and gave a signiﬁcant improve-
ment in performance up to 1 year prior to diagnosis and with
improved lead times of detection.
Initial proteomic proﬁling of pooled sera identiﬁed a number of
potential biomarkers that were elevated in cancer cases compared
to controls. One of these was PEBP4, a suppressor of proliferation
and invasion in ovarian tumour cell lines,32 and a RAF1- and MEK1-
binding protein that inhibits tumour necrosis factor-α-induced
apoptosis.33 PEBP4 was signiﬁcantly elevated in sera from cancer
cases prior to diagnosis and featured in one of the top
multivariable longitudinal models. CHI3L1 also featured in two
of the best models, and while we showed it not to be
discriminatory alone, it complemented CA125 when used long-
itudinally. This highlights the importance of not discounting
candidates based on univariate analysis alone. CHI3L1 is a
carbohydrate-binding lectin with a purported role in tissue
remodelling, angiogenesis and survival that may function by
modulating chemokine and inﬂammatory responses. It has been
previously reported as a serum marker of ovarian cancer34 and, in
one study, outperformed CA125 for detecting early-stage dis-
ease.35 Our previous work had identiﬁed elevated levels of
secreted CHI3L1 in immortalised ovarian surface epithelial cells
transformed with either MYC or MYC plus activated KRAS-G12V,
suggesting that its overexpression may be an early event in
epithelial cell transformation.24 AGR2 also complemented CA125
and CHI3L1 in one of the top models. AGR2 is a secreted and
endoplasmic reticulum-resident chaperone protein required for
folding, trafﬁcking and assembly of cysteine-rich transmembrane
receptors and mucins. Its overexpression in numerous cancer
types has been linked with enhanced cell migration and
proliferation, altered adhesion and differentiation and promotion
of angiogenesis and metastasis.36 Previous studies have found
elevated tissue expression of AGR2 to be an indicator of poor
prognosis,37 and it has been reported as a putative blood-borne
biomarker for the detection and/or prognosis of ovarian,
pancreatic, prostate and lung cancer.25,38–40 Our ﬁndings support
AGR2 as a biomarker for early ovarian cancer detection that
complements CA125 (and CHI3L1) when used longitudinally.
A major challenge in early detection is how best to normalise a
biomarker to natural variations in serum levels within individuals
and across populations. By analysing longitudinal data using the
described indices, we have deﬁned changes in biomarker levels
that deviate from individual baselines providing greatly improved
performance compared to simple cut-off models. This type of
approach was used successfully to develop the ROCA, where serial
CA125 measurements were used to substantially improve on
using single CA125 measurements.18 In agreement, the best single
marker in our data set was longitudinal CA125 using Index 3
(CA125{3}), which provided higher sensitivity at ﬁxed speciﬁcity
compared to using the ﬁnal CA125 measurement, although the
increase was not signiﬁcant. However, by combining longitudin-
ally indexed markers (including CA125), we show signiﬁcant
improvement in sensitivity and lead time over using CA125 alone.
The sensitivity of the CA125 cut-off model used herein (71.4%,
95% CI 53.6–85.7) was similar to that reported previously using a
validation set of 25,042 UKCTOCS women (73.1%, 95% CI
63.6–80.8) at 90% speciﬁcity.21 This demonstrates that the
distribution of CA125 in our data set is representative of the
whole of UKCTOCS. Comparison with performance of published
serial CA125 algorithms applied to the whole UKCTOCS cohort as
ﬁrst-line screening tests shows our models gave higher sensitivity
at similar speciﬁcity. Four of the models gave 92.9% sensitivity
(95% CI 78.6–100) at 90.3% speciﬁcity, compared to MMT with
86.5% sensitivity (95% CI 78.4–91.9) at 89.5% speciﬁcity, PEB with
88.5% sensitivity (95% CI 80.6–93.4) at 89.5% speciﬁcity, and ROCA
with 87.1% sensitivity at 87.6% speciﬁcity.18,21 The best model
(CA125{3}AGR2{3}CHI3L1{3}) also substantially outperformed these
serial CA125 algorithms at 1–2 years to diagnosis, with a sensitivity
of 37.5% versus 23.3% for MMT and 26.7% for PEB,21 detecting
cancers earlier. Moreover, for the more aggressive Type II cases,
our models provided 100% sensitivity at 90.3% speciﬁcity at 1 year
to diagnosis. Thus we have demonstrated that combining
additional markers longitudinally improves detection rate and
lead time compared to using CA125 alone.
The key strengths of our study are the use of a novel
combination of longitudinal biomarker measurements using pre-
diagnosis serial samples from a well-characterised cohort, with
rigorous variable selection and model testing that compared
poor prognosis cancers with all cancer cases. The main weakness
of this discovery study was the small sample size used, with
samples from 6 Type I and 22 Type II cases used for model
testing; some cases were excluded as they lacked an annual
UKCTOCS sample taken within 1 year to diagnosis, and we used
controls only from women who had not been diagnosed with
any cancer at sample donation and during follow-up; the latter
may exaggerate speciﬁcity. The small sample size and hetero-
geneous nature of the cases also precluded any meaningful
subset analysis. Despite rigorous variable selection and cross-
validation, we cannot rule out the potential for overﬁtting and it
is now essential to validate these models in a larger independent
cohort of samples with more detailed investigation of lead time
and model performance by stage and histological subtype.
Nevertheless, the ﬁndings are encouraging and advocate the
beneﬁts of incorporating serial sampling into biomarker dis-
covery and clinical testing studies.
In conclusion, we have generated multimarker longitudinal
models for the early detection of ovarian cancer that signiﬁcantly
outperform CA125, detecting Type I and II cases that CA125 did
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not. Furthermore, we show the potential of these models to
improve lead time. Blinded validation of these models in a larger,
longitudinal sample set is now warranted to investigate the
potential of these algorithms for early detection in ovarian cancer
screening.
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